<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988204</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 18-1283</org_study_id>
    <nct_id>NCT04988204</nct_id>
  </id_info>
  <brief_title>Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Pilot Study: Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) is a rapidly growing epidemic worldwide and is an&#xD;
      increasingly important etiology of chronic liver disease and hepatocellular carcinoma. NAFLD&#xD;
      affects approximately 90 million people in the United States (US) amounting to an annual cost&#xD;
      of $100 billion yearly. It is projected to become the leading cause of liver transplantation&#xD;
      in the US by 2030 and is associated with significant morbidity and mortality. NAFLD is a&#xD;
      spectrum of liver diseases, ranging from simple steatosis (nonalcoholic fatty liver, NAFL) to&#xD;
      hepatic steatosis associated with inflammation (nonalcoholic steatohepatitis, NASH), which&#xD;
      can be associated with liver scarring (hepatic fibrosis) and cirrhosis. There are limited&#xD;
      therapeutic options that have been shown to effectively reduce or reverse the progression of&#xD;
      disease.&#xD;
&#xD;
      Lifestyle modification is the backbone of therapy, but difficult to achieve. A modest amount&#xD;
      of weight loss of approximately 3% can reduce liver steatosis and a 10% weight loss can&#xD;
      reduce the NASH and improve liver fibrosis. The American Association of the Study of Liver&#xD;
      Diseases (AASLD) guidelines state that &quot;a combination of a hypocaloric diet (daily reduction&#xD;
      by 500-1000 kcal) and moderate intensity exercise is the best likelihood of sustaining weight&#xD;
      loss over time.&quot; There are several barriers to adopting a healthy lifestyle involving both&#xD;
      patient and physician limitations. The aim of this study is to engage patients in a lifestyle&#xD;
      intervention program that has already been shown to be successful in achieving weight loss&#xD;
      goals and adopting healthier lifestyle patterns.&#xD;
&#xD;
      The CDC Diabetes Prevention Program, (DPP) was a large (n=3,234) multicenter study aimed to&#xD;
      evaluate the effect of lifestyle intervention or treatment with metformin on the incidence of&#xD;
      type 2 diabetes (T2DM). Lifestyle intervention reduced the incidence of T2DM by 58% (95% CI,&#xD;
      48-66%) and metformin reduced the incidence by 31% (95% CI, 17-43%) as compared to placebo.&#xD;
      To prevent one case of diabetes over three years, 6.9 persons would have to participate in&#xD;
      the lifestyle-intervention program, and 13.9 would have to receive metformin. The CDC DPP&#xD;
      program has been adapted and tested in the multiple different community and state-wide&#xD;
      programs including the YMCA, WorkWellNYC and NYS DPP. In these real-world models, the life&#xD;
      style intervention program has been delivered in a group-based format by DPP lifestyle&#xD;
      coaches. These programs have been successful like that of the randomized trial and&#xD;
      improvements were sustainable at 6 and 12 month follow up after completion of the program.&#xD;
      The program is now available and reimbursable through Medicare (Medicare Diabetes Prevention&#xD;
      Program).&#xD;
&#xD;
      In this pilot study, the researchers will enroll 20 patients with NAFLD in an adapted DPP&#xD;
      program and follow study participants for 1 year. The rationale for the proposed research is&#xD;
      to apply the DPP to NAFLD because of the close relationship with Diabetes and determine the&#xD;
      real-world outcome of the DPP program on weight loss in patients with NAFLD. If the&#xD;
      researchers illustrate that weight loss can be achieved and is sustainable in patients with&#xD;
      NAFLD enrolled in lifestyle intervention programs, the researchers can develop innovative&#xD;
      approaches to deliver such a program nationwide in a cost-effective and sustainable manner.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 3, 2018</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants in the program at the end of the study</measure>
    <time_frame>12 months</time_frame>
    <description>Retention defined as number of patients in the program at the end of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Change in Weight at 12 months as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic steatosis via Fibroscan</measure>
    <time_frame>Baseline</time_frame>
    <description>Changes in hepatic steatosis measured with fibroscan using the controlled attenuated parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic steatosis via Fibroscan</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in hepatic steatosis measured with fibroscan using the controlled attenuated parameter .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic steatosis via Fibroscan</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in hepatic steatosis measured with fibroscan using the controlled attenuated parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated A1C</measure>
    <time_frame>Baseline</time_frame>
    <description>Glycosylated A1C in assessing metabolic comorbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated A1C</measure>
    <time_frame>6 months</time_frame>
    <description>Glycosylated A1C in assessing metabolic comorbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated A1C</measure>
    <time_frame>12 months</time_frame>
    <description>Glycosylated A1C in assessing metabolic comorbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Lipid levels in assessing metabolic comorbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid levels</measure>
    <time_frame>6 months</time_frame>
    <description>Lipid levels in assessing metabolic comorbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid levels</measure>
    <time_frame>12 months</time_frame>
    <description>Lipid levels in assessing metabolic comorbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Liver enzymes levels for ALT, AST, and ALP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes levels</measure>
    <time_frame>6 months</time_frame>
    <description>Liver enzymes levels for ALT, AST, and ALP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes levels</measure>
    <time_frame>12 months</time_frame>
    <description>Liver enzymes levels for ALT, AST, and ALP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin level</measure>
    <time_frame>Baseline</time_frame>
    <description>Liver enzyme level for Bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin level</measure>
    <time_frame>6 months</time_frame>
    <description>Liver enzyme level for Bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin level</measure>
    <time_frame>12 months</time_frame>
    <description>Liver enzyme level for Bilirubin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in 1 year program</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diabetes Prevention Program</intervention_name>
    <description>The Diabetes Prevention Program is a 1 year validated program to prevent the development of type 2 diabetes. Participants with NAFLD will engage will work with a CDC certified DPP certified lifestyle coach and other participants in a group setting during the study focusing on lifestyle changes to achieve weight loss and improvement in NAFLD.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of NAFLD, defined by the presence of hepatic steatosis with vibration&#xD;
             controlled transient elastography (VCTE) controlled attenuation parameter (CAP)&#xD;
             measurement over 240dB/m, or liver biopsy showing macrovesicular steatosis in â‰¥ 5% of&#xD;
             hepatocytes.&#xD;
&#xD;
          -  patients were 18 years and older,&#xD;
&#xD;
          -  fluent in English (the program could only be conducted in English by the DPP-certified&#xD;
             coach),&#xD;
&#xD;
          -  able to meet program scheduling requirements, and able to participate in physical&#xD;
             activity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  additional causes of liver disease such as viral hepatitis, biliary obstruction,&#xD;
             hepatocellular carcinoma, Wilson's disease, Budd Chiari Syndrome, autoimmune&#xD;
             hepatitis, alcoholic liver disease or alcohol use (&gt;20g/day women, &gt;30g/day men),&#xD;
&#xD;
          -  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values &gt;300 U/L,&#xD;
&#xD;
          -  using steatogenic medications (amiodarone, methotrexate, tamoxifen, and&#xD;
             corticosteroids),&#xD;
&#xD;
          -  pregnant,&#xD;
&#xD;
          -  a history of liver transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amreen Dinani</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine, Division of Liver Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Union Square</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Amreen Dinani</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>was not including inn protocol and consent form</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

